A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL)

Clinical Trial ID NCT01212991

PubWeight™ 61.93‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01212991

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014 11.05
2 Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2011 2.68
3 Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol 2015 2.41
4 New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011 2.01
5 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
6 Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 2014 1.31
7 Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 2012 1.25
8 Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2013 1.22
9 Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016 1.21
10 Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 2013 1.19
11 Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit. Clin Cancer Res 2013 1.13
12 Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol 2013 1.12
13 Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol 2011 1.05
14 Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J 2011 1.04
15 Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res 2013 1.00
16 The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013 0.97
17 Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol 2014 0.96
18 Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011 0.93
19 Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate 2014 0.92
20 Prostate cancer in 2011: redefining the therapeutic landscape for CRPC. Nat Rev Urol 2012 0.91
21 Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist 2011 0.90
22 Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012 0.89
23 Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer. Ther Adv Urol 2013 0.89
24 Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat Rev Urol 2013 0.87
25 Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl 2011 0.87
26 Novel agents in the management of castration resistant prostate cancer. J Carcinog 2014 0.87
27 Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer. Cancer Biol Ther 2013 0.85
28 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
29 Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. Drug Des Devel Ther 2013 0.83
30 Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol 2015 0.82
31 Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evid 2013 0.82
32 Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev Anticancer Ther 2014 0.82
33 Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol 2016 0.82
34 Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. Int J Biol Sci 2016 0.81
35 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
36 U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Oncologist 2015 0.81
37 Abiraterone acetate. Nat Rev Drug Discov 2011 0.80
38 Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs 2013 0.80
39 Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. Cancer Biol Ther 2012 0.79
40 An update on enzalutamide in the treatment of prostate cancer. Ther Adv Urol 2015 0.79
41 New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer 2011 0.79
42 Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect Comparison. Clin Med Insights Oncol 2014 0.79
43 Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist 2013 0.78
44 Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer. Asian J Androl 2012 0.78
45 Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 2011 0.78
46 Metastatic castration-resistant prostate cancer: critical review of enzalutamide. Clin Med Insights Oncol 2013 0.78
47 A changing landscape in castration-resistant prostate cancer treatment. Front Endocrinol (Lausanne) 2012 0.78
48 Radium-223 chloride: a new treatment option for metastatic castration-resistant prostate carcinoma. Drugs R D 2012 0.77
49 Prostate cancer: Are urologists ready to manage castration-resistant disease? Nat Rev Urol 2013 0.77
50 Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer. Drug Discov Today Ther Strateg 2010 0.76
51 The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients. Investig Clin Urol 2016 0.75
52 Castrate-resistant prostate cancer: postdocetaxel management. Curr Opin Urol 2013 0.75
53 Management of metastatic castration-resistant prostate cancer. Eur Urol Rev 2011 0.75
54 Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks. Nat Rev Clin Oncol 2012 0.75
Next 100